PMID- 35570525
OWN - NLM
STAT- MEDLINE
DCOM- 20220919
LR  - 20221027
IS  - 1873-4251 (Electronic)
IS  - 1570-162X (Linking)
VI  - 20
IP  - 3
DP  - 2022
TI  - Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naive 
      Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
PG  - 222-227
LID - 10.2174/1570162X20666220514165728 [doi]
AB  - INTRODUCTION: This preliminary real-world study (RWS) was designed to evaluate 
      the antiviral efficacy, safety, and feasibility of the 2-drug regimen (2DR), 
      dolutegravir plus lamivudine as the initial antiretroviral therapy (ART) among 
      antiretroviral (ARV)-naive adults with HIV-1 in West China. METHODS: This RWS 
      included the treatment of treatment-naive adults applying 2DR of dolutegravir 50 
      mg once daily (QD) plus lamivudine 300mg QD with negative HBsAg from one single 
      center of People's Hospital of Chongqing Banan District in West China. Viral load 
      (VL), CD4+ T-cell count, and laboratory indicators were collected at baseline; 
      weeks 4, 12, and 24, and thereafter every 24 weeks up to 144 weeks. The primary 
      endpoint was the proportion of patients with HIV-1 RNA <50 copies/mL at week 24. 
      RESULTS: A total of 54 ART-naive patients were treated with the 2-drug regimen of 
      DTG plus 3TC and were enrolled in this study since April 1st, 2020. Twenty-one 
      patients received 24-week VL tests at screening as required by inclusion 
      criteria. Median HIV-1 RNA at entry was 95,700 copies/ mL (interquartile range 
      (IQR): 28,300-310,000) and the median baseline CD4+ cell count was 249 per cubic 
      millimetre(IQR: 118-310). At week 24, 15 (71.4%) of 21 participants achieved 
      virological success, defined as HIV-1 RNA < 50 copies/mL, while 10 (90.9%) of 11 
      participants with a baseline HIV-1 RNA < 100,000 copies/mL achieved virological 
      success compared with 5 (50%) of 10 participants with a baseline HIV-1 RNA 
      >/=100,000 copies/mL [Relative Risk (RR) 1.818; 95% CI 1.018-1.927]. In 
      participants with CD4+ cell counts >/= 200 cells/mm3, 9 (75%) of 12 participants 
      achieved virological success compared with 6 (66.7%) of 9 participants with 
      baseline CD4+ cell count < 200 cells/mm3 achieved it (RR 1.124; 95% CI 
      0.641-1.970). No major tolerability/toxicity issues were observed. CONCLUSION: 
      This real-world study suggested that the 2-drug regimen of DTG plus 3TC could be 
      considered as an alternative for ART-naive patients in West China, especially 
      with HIV-1 RNA less than 100,000 copies/mL at baseline, regarding the limits of 
      viral load test frequency and the absence of HIV genotypic testing of viral 
      resistance.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Hui, Xia
AU  - Hui X
AD  - Department of Infection, People's hospital of Chongqing Banan District, 
      Chongqing, China.
FAU - Gan, Xinrong
AU  - Gan X
AD  - Department of Infection, People's hospital of Chongqing Banan District, 
      Chongqing, China.
FAU - Li, Qian
AU  - Li Q
AD  - Department of Infection, People's hospital of Chongqing Banan District, 
      Chongqing, China.
FAU - Sun, Wei
AU  - Sun W
AD  - Department of Infection, People's hospital of Chongqing Banan District, 
      Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Curr HIV Res
JT  - Current HIV research
JID - 101156990
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Antiviral Agents)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Oxazines)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - 0 (RNA, Viral)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 63231-63-0 (RNA)
RN  - DKO1W9H7M1 (dolutegravir)
SB  - IM
MH  - Adult
MH  - *Anti-HIV Agents/adverse effects
MH  - Anti-Retroviral Agents/therapeutic use
MH  - Antiviral Agents/therapeutic use
MH  - Drug Therapy, Combination
MH  - *HIV Infections/drug therapy
MH  - *HIV Seropositivity/drug therapy
MH  - *HIV-1/genetics
MH  - Hepatitis B Surface Antigens/therapeutic use
MH  - Heterocyclic Compounds, 3-Ring/adverse effects
MH  - Humans
MH  - Lamivudine/adverse effects
MH  - Oxazines
MH  - Piperazines
MH  - Pyridones
MH  - RNA/therapeutic use
MH  - RNA, Viral
MH  - Viral Load
OTO - NOTNLM
OT  - 2-drug regimen
OT  - HIV
OT  - dolutegravir plus lamivudine
OT  - effectiveness
OT  - integrase strand transfer inhibitor
OT  - simplification
EDAT- 2022/05/17 06:00
MHDA- 2022/09/20 06:00
CRDT- 2022/05/16 02:43
PHST- 2021/11/09 00:00 [received]
PHST- 2022/02/22 00:00 [revised]
PHST- 2022/03/16 00:00 [accepted]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/09/20 06:00 [medline]
PHST- 2022/05/16 02:43 [entrez]
AID - CHR-EPUB-123571 [pii]
AID - 10.2174/1570162X20666220514165728 [doi]
PST - ppublish
SO  - Curr HIV Res. 2022;20(3):222-227. doi: 10.2174/1570162X20666220514165728.